Aethlon Medical to merge with North Immunology; Nasdaq listing planned

Aethlon Medical will merge with North Immunology, seeking a Nasdaq listing under ticker NRTX backed by an oversubscribed $180M PIPE to fund operations into H2 2028, with NOR—101 targeted toward a Phase 1a trial in 2027; pre-merger AEMD holders would own ~4.75%.